Werewolf Therapeutics Inc (HOWL) News

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”...

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”...

Form 8-K - Current report

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

–  Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial...

Form 8-K - Current report

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor...

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b...

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations...

Form 8-K - Current report